Free Trial
→ The investigation Porter spent tens of thousands to document (From Porter & Company) (Ad)tc pixel Free UG Stock Alerts

United-Guardian (UG) Competitors

United-Guardian logo
$8.63 +0.04 (+0.47%)
Closing price 11/12/2026 04:00 PM Eastern
Extended Trading
$8.61 -0.02 (-0.23%)
As of 11/12/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

UG vs. ZNTL, MENS, RFAI, SBTX, and LENZ

Should you buy United-Guardian stock or one of its competitors? United-Guardian's main competitors and comparable companies include Zentalis Pharmaceuticals (ZNTL), Jyong Biotech (MENS), RF Acquisition Corp II (RFAI), Silverback Therapeutics (SBTX), and LENZ Therapeutics (LENZ). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does United-Guardian compare to Zentalis Pharmaceuticals?

United-Guardian (NASDAQ:UG) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership.

United-Guardian has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.91, meaning that its stock price is 91% more volatile than the broader market.

Zentalis Pharmaceuticals has a consensus price target of $8.29, indicating a potential upside of 393.20%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Zentalis Pharmaceuticals is more favorable than United-Guardian.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
United-Guardian
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Zentalis Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.80

United-Guardian has a net margin of 25.16% compared to Zentalis Pharmaceuticals' net margin of 0.00%. United-Guardian's return on equity of 27.80% beat Zentalis Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
United-Guardian25.16% 27.80% 23.82%
Zentalis Pharmaceuticals N/A -75.82%-55.15%

23.2% of United-Guardian shares are owned by institutional investors. 29.0% of United-Guardian shares are owned by company insiders. Comparatively, 3.8% of Zentalis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Zentalis Pharmaceuticals had 15 more articles in the media than United-Guardian. MarketBeat recorded 20 mentions for Zentalis Pharmaceuticals and 5 mentions for United-Guardian. Zentalis Pharmaceuticals' average media sentiment score of 0.70 beat United-Guardian's score of 0.65 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
United-Guardian
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Zentalis Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

United-Guardian has higher earnings, but lower revenue than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than United-Guardian, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
United-Guardian$10.55M3.75$2.11M$0.6812.69
Zentalis Pharmaceuticals$67.43M1.79-$137.06M-$1.92N/A

Summary

United-Guardian beats Zentalis Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does United-Guardian compare to Jyong Biotech?

United-Guardian (NASDAQ:UG) and Jyong Biotech (NASDAQ:MENS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
United-Guardian
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Jyong Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

United-Guardian has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market. Comparatively, Jyong Biotech has a beta of 2.52, indicating that its share price is 152% more volatile than the broader market.

23.2% of United-Guardian shares are owned by institutional investors. 29.0% of United-Guardian shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, United-Guardian had 4 more articles in the media than Jyong Biotech. MarketBeat recorded 5 mentions for United-Guardian and 1 mentions for Jyong Biotech. Jyong Biotech's average media sentiment score of 1.82 beat United-Guardian's score of 0.65 indicating that Jyong Biotech is being referred to more favorably in the news media.

Company Overall Sentiment
United-Guardian Positive
Jyong Biotech Very Positive

United-Guardian has a net margin of 25.16% compared to Jyong Biotech's net margin of 0.00%. United-Guardian's return on equity of 27.80% beat Jyong Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
United-Guardian25.16% 27.80% 23.82%
Jyong Biotech N/A N/A N/A

United-Guardian has higher revenue and earnings than Jyong Biotech.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
United-Guardian$10.55M3.75$2.11M$0.6812.69
Jyong BiotechN/AN/A-$4.67MN/AN/A

Summary

United-Guardian beats Jyong Biotech on 9 of the 11 factors compared between the two stocks.

How does United-Guardian compare to RF Acquisition Corp II?

United-Guardian (NASDAQ:UG) and RF Acquisition Corp II (NASDAQ:RFAI) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.

In the previous week, United-Guardian had 3 more articles in the media than RF Acquisition Corp II. MarketBeat recorded 5 mentions for United-Guardian and 2 mentions for RF Acquisition Corp II. RF Acquisition Corp II's average media sentiment score of 0.91 beat United-Guardian's score of 0.65 indicating that RF Acquisition Corp II is being referred to more favorably in the news media.

Company Overall Sentiment
United-Guardian Positive
RF Acquisition Corp II Positive

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
United-Guardian
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
RF Acquisition Corp II
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

United-Guardian has higher revenue and earnings than RF Acquisition Corp II.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
United-Guardian$10.55M3.75$2.11M$0.6812.69
RF Acquisition Corp IIN/AN/AN/AN/AN/A

23.2% of United-Guardian shares are held by institutional investors. 29.0% of United-Guardian shares are held by insiders. Comparatively, 39.1% of RF Acquisition Corp II shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

United-Guardian has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market. Comparatively, RF Acquisition Corp II has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market.

United-Guardian has a net margin of 25.16% compared to RF Acquisition Corp II's net margin of 0.00%. United-Guardian's return on equity of 27.80% beat RF Acquisition Corp II's return on equity.

Company Net Margins Return on Equity Return on Assets
United-Guardian25.16% 27.80% 23.82%
RF Acquisition Corp II N/A N/A N/A

Summary

United-Guardian beats RF Acquisition Corp II on 6 of the 9 factors compared between the two stocks.

How does United-Guardian compare to Silverback Therapeutics?

Silverback Therapeutics (NASDAQ:SBTX) and United-Guardian (NASDAQ:UG) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

United-Guardian has a net margin of 25.16% compared to Silverback Therapeutics' net margin of 0.00%. United-Guardian's return on equity of 27.80% beat Silverback Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Silverback TherapeuticsN/A -29.62% -28.20%
United-Guardian 25.16%27.80%23.82%

In the previous week, United-Guardian had 5 more articles in the media than Silverback Therapeutics. MarketBeat recorded 5 mentions for United-Guardian and 0 mentions for Silverback Therapeutics. United-Guardian's average media sentiment score of 0.65 beat Silverback Therapeutics' score of 0.00 indicating that United-Guardian is being referred to more favorably in the news media.

Company Overall Sentiment
Silverback Therapeutics Neutral
United-Guardian Positive

United-Guardian has higher revenue and earnings than Silverback Therapeutics. Silverback Therapeutics is trading at a lower price-to-earnings ratio than United-Guardian, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silverback TherapeuticsN/AN/A-$89.48M-$2.42N/A
United-Guardian$10.55M3.75$2.11M$0.6812.69

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Silverback Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
United-Guardian
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

74.9% of Silverback Therapeutics shares are held by institutional investors. Comparatively, 23.2% of United-Guardian shares are held by institutional investors. 34.4% of Silverback Therapeutics shares are held by insiders. Comparatively, 29.0% of United-Guardian shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Silverback Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market. Comparatively, United-Guardian has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market.

Summary

United-Guardian beats Silverback Therapeutics on 11 of the 13 factors compared between the two stocks.

How does United-Guardian compare to LENZ Therapeutics?

LENZ Therapeutics (NASDAQ:LENZ) and United-Guardian (NASDAQ:UG) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

United-Guardian has a net margin of 25.16% compared to LENZ Therapeutics' net margin of -1,134.97%. United-Guardian's return on equity of 27.80% beat LENZ Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
LENZ Therapeutics-1,134.97% -59.56% -54.75%
United-Guardian 25.16%27.80%23.82%

LENZ Therapeutics currently has a consensus target price of $14.75, suggesting a potential upside of 260.64%. Given LENZ Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe LENZ Therapeutics is more favorable than United-Guardian.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LENZ Therapeutics
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43
United-Guardian
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

United-Guardian has lower revenue, but higher earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than United-Guardian, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LENZ Therapeutics$19.09M6.73-$82.13M-$4.49N/A
United-Guardian$10.55M3.75$2.11M$0.6812.69

54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 23.2% of United-Guardian shares are held by institutional investors. 8.3% of LENZ Therapeutics shares are held by company insiders. Comparatively, 29.0% of United-Guardian shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

LENZ Therapeutics has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, United-Guardian has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market.

In the previous week, United-Guardian had 1 more articles in the media than LENZ Therapeutics. MarketBeat recorded 5 mentions for United-Guardian and 4 mentions for LENZ Therapeutics. United-Guardian's average media sentiment score of 0.65 beat LENZ Therapeutics' score of 0.61 indicating that United-Guardian is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
LENZ Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
United-Guardian
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

United-Guardian beats LENZ Therapeutics on 10 of the 16 factors compared between the two stocks.

Get United-Guardian News Delivered to You Automatically

Sign up to receive the latest news and ratings for UG and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

UG vs. The Competition

Export
MetricUnited-GuardianPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$39.47M$13.79B$7.91B$12.24B
Dividend Yield6.98%2.56%2.46%4.51%
P/E Ratio12.6325.6934.3428.42
Price / Sales3.757.728.906.01
Price / Cash17.8215.7922.2322.80
Price / Book3.545.244.503.83
Net Income$2.11M$2.87B$3.51B$390.69M
7 Day Performance28.61%0.49%-0.71%0.52%
1 Month Performance25.80%-3.55%-3.15%-6.02%
1 Year Performance39.87%-6.02%1.13%-5.24%

United-Guardian Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
UG
United-Guardian
1.5714 of 5 stars		$8.63
+0.5%		N/A+40.6%$39.47M$10.55M12.6325
ZNTL
Zentalis Pharmaceuticals
4.5081 of 5 stars		$1.88
+4.2%		$7.75
+313.3%		+25.4%$134.38M$67.43MN/A106
MENS
Jyong Biotech
N/A$1.77
-1.4%		N/A-95.4%$134.19MN/AN/A27
RFAI
RF Acquisition Corp II
1.5234 of 5 stars		$37.18
+11.0%		N/A+209.4%$130.60MN/AN/A2
SBTX
Silverback Therapeutics
N/A$3.57
+13.3%		N/A-55.0%$128.73MN/AN/A83

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:UG) was last updated on 11/13/2026 by MarketBeat.com Staff.
From Our Partners
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...
Base Camp Trading | Sponsoredtc pixel
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a...
Traders Agency | Sponsoredtc pixel
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...
Behind the Markets | Sponsoredtc pixel
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...
Paradigm Press | Sponsoredtc pixel
Uranium Mine Flood That Sparked a 2006 Price Surge Returns
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...
Digest Publishing | Sponsoredtc pixel
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...
Weiss Ratings | Sponsoredtc pixel